Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.36 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10216187 | 0.80 | CHRNB2 (0.41) | TBK1IKBKEALDH1A1KMT2AKIF11 | |
| SCHEMBL21649228 | 0.80 | GRM4 (0.42) | TBK1IKBKEALDH1A1KMT2AKIF11 | |
| SCHEMBL18687390 | 0.79 | TRPA1 (0.40) | TBK1IKBKEALDH1A1KMT2AKIF11 | |
| SCHEMBL12546215 | 0.79 | TBK1 (0.45) | TBK1IKBKESMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL22672604 | 0.77 | TBK1 (0.44) | TBK1IKBKESMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL20884969 | 0.76 | TBK1 (0.34) | TBK1IKBKEALDH1A1KMT2AKIF11 | |
| SCHEMBL23474002 | 0.76 | MAPT (0.42) | SMN1; SMN2ALDH1A1KMT2AESR1ESR2 | |
| SCHEMBL1839676 | 0.75 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1KMT2AESR1ESR2 | |
| SCHEMBL24201459 | 0.75 | TBK1 (0.36) | TBK1IKBKEALDH1A1KMT2ATHRB | |
| SCHEMBL7124248 | 0.72 | ACHE (0.41) | SMN1; SMN2ALDH1A1KMT2ATHRBESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| US-20210171461-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
| US-20210171531-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171531-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | TBK1 3264/4885IKBKE 2414/4885SMN1; SMN2 1476/4885 |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | TBK1 3264/4885IKBKE 2414/4885SMN1; SMN2 1476/4885 |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | TBK1 3264/4885IKBKE 2414/4885SMN1; SMN2 1476/4885 |
| US-20210171461-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | TBK1 3264/4885IKBKE 2414/4885SMN1; SMN2 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.